Upcoming AWS Coverage on Cencosud Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 23, 2017 / Active Wall St. announces its post-earnings coverage on Staples, Inc. (NASDAQ: SPLS). The Company released its financial results for its fourth quarter and fiscal 2016 on March 08, 2017. The office supply chain missed top-line expectations. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Staples’ competitors within the Specialty Retail, Other space, Cencosud S.A. (NYSE: CNCO), reported on March 02, 2017, its Q4 and full year 2016 results. AWS will be initiating a research report on Cencosud in the coming days.

Today, AWS is promoting its earnings coverage on SPLS; touching on CNCO. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

For the quarter ended January 28, 2017, Staples’ sales were $4.56 billion, down 3% compared to Q4 FY15 sales of $4.70 billion. Total company comparable sales for Q4 FY16 declined 0.9% on a y-o-y basis. Staples’ sales numbers lagged behind analysts’ consensus of $5.02 billion. For the full year 2016, Staples sales fell 3% to $18.25 billion compared to FY15 sales of $18.76 billion. Total Company comparable sales declined 0.7% on a y-o-y basis.

Staples’ gross profit rate improved by 93 basis points year-over-year to 27.1% in Q4 FY16, while gross profit grew by $7 million to $1.23 billion.

For Q4 FY16, on a GAAP basis, Staples reported a net loss from continuing operations of $615 million, or $0.94 per share. The Company’s reported quarter results from continuing operations include pre-tax charges of $791 million primarily related to goodwill impairment, restructuring costs, and the impairment of long-lived assets. Excluding the impact of charges, the Company reported non-GAAP net income from continuing operations of $161 million, or $0.25 per diluted share, versus Q4 FY15 non-GAAP net income from continuing operations of $168 million, or $0.26 per diluted share. The Company’s earnings numbers met market estimates of $0.25 per share.

For FY16, on a GAAP basis, Staples reported a net loss from continuing operations of $459 million, or $0.71 per share, compared to net income of $462 million, or $0.71 per diluted share, in FY15. On a non-GAAP basis, the Company reported net income from continuing operations of $586 million, or $0.90 per diluted share, during 2016 compared to $598 million, or $0.93 per diluted share, in the prior year.

New Segment Reporting Structure

During Q4 FY16, Staples changed its business segments to align with its 20/20 strategic plan, and reflect its priorities to accelerate growth in North American Delivery and preserve profit in North American Retail. Under the new structure, the North American Delivery segment includes Staples Business Advantage, staples.com, staples.ca, and quill.com. The North American Retail segment includes the Company’s retail stores in the US and Canada.

For Q4 FY16, Staples’ North American Delivery sales were $2.6 billion, down 1% on a y-o-y basis. The Company’s North American Delivery comparable sales grew 1% compared to the year ago same period. The segment’s operating income rate increased 10 basis points to 6.4% compared to Q4 2015. This improvement primarily reflects increased product margin rate.

During Q4 FY16, Staples’ North American Retail sales totaled $1.6 billion, down 8% on a y-o-y basis. The Company stated that Store closures negatively impacted reported quarter sales growth by approximately 2%. Comparable store sales fell 7% on a y-o-y basis. The segment’s operating income rate came in at 6.0%, up 11 basis points on a y-o-y basis.

Staples closed 13 stores during Q4 FY16 and 48 stores for the full year in North America and ended the year with 1,255 stores in the US and 304 stores in Canada.

Discontinued Operations

During Q4 FY16, Staples completed the sale of its retail business in the United Kingdom. The Company also entered into an agreement to sell a controlling interest in its remaining European operations during the reported quarter, and completed the transaction in February 2017. As a result of these transactions, the results of Staples’ European operations have been classified as discontinued operations. The Company recorded an after-tax loss from discontinued operations of $337 million in Q4 FY16, which includes $231 million of pre-tax charges related to impairment of long-lived assets and a $114 million pre-tax loss on the sale of the Company’s retail business in the UK. This compared to an after-tax loss of $44 million from discontinued operations in Q4 FY15.

Balance Sheet

Staples generated $934 million of cash provided by operating activities, spent $255 million in capital expenditures, and generated $889 million of adjusted free cash flow in 2016 excluding the after-tax impact to cash provided by operating activities of $210 million related to charges associated with financing for the proposed acquisition of Office Depot and costs associated with the termination of the Office Depot merger agreement. The Company returned $311 million to shareholders through cash dividends in 2016. Staples ended Q4 FY16 with $2.2 billion in liquidity, including $1.1 billion in cash and cash equivalents.

On March 07, 2017, Staples announced that its Board of Directors has declared a quarterly cash dividend on Staples’ common stock of $0.12 per share. The dividend is payable on April 13, 2017, to shareholders of record on March 24, 2017.

Sells Australia and New Zealand Business

On March 13, 2017, Staples and Platinum Equity announced a definitive agreement under which Platinum Equity will acquire Staples’ business in Australia and New Zealand for an undisclosed sum. The transaction is expected to close in Q2 2017.

Platinum Equity is a leading global private equity firm with a highly specialized focus on business operations and more than 20 years’ experience acquiring and operating businesses that have been part of large corporate entities. Platinum Equity, which has portfolio Company operations on all seven continents, has been actively pursuing investment opportunities in Australia and New Zealand and currently owns a majority stake in Sensis, an Australian directories business acquired from Telstra.

Following the transition to the new ownership, the divested business will continue to operate under the Staples brand in Australia and New Zealand for a short period of time while a new corporate brand is created.

Outlook

For Q1 FY17, Staples expects to achieve fully diluted non-GAAP earnings per share from continuing operations in the range of $0.15 to $0.18. For the full year 2017, the Company expects to generate at least $500 million of free cash flow. Staples Inc. plans to close approximately 70 stores in North America in 2017.

Stock Performance

At the close of trading session on Wednesday, March 22, 2017, Staples’ stock price fell 1.50% to end the day at $8.51. A total volume of 4.85 million shares were exchanged during the session. The Company’s share price has gained 3.28% in the past six months. The stock currently has a market cap of $5.55 billion and has a dividend yield of 5.64%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458003

VANCOUVER, BC / ACCESSWIRE / March 23, 2017 / Cloud Nine Education Group Ltd. (CSE: CNI) (the “Company” or “Cloud Nine”) is pleased to announce that it has reached an agreement to provide its ESL curriculum at a prodigious private school located in central Canada. At the request of the client, Cloud Nine has agreed to not to disclose the institution’s identity until May when the 2017 marketing campaign is fully underway.

The agreement positions Cloud Nine as their new client’s exclusive ESL curriculum provider through 2020. The exclusivity provision applies to both the institution’s summer camp program and to a year-round ESL study center that the client is obligated to open in 2017 at no cost to Cloud Nine. The fee structure provides a premium to those Cloud Nine currently applies in Latin America.

In discussing the agreement, Company President & CEO, Michael Hunter said, “We are very pleased to have a reached a multi-year contract with one of Canada’s oldest and most prestigious independent schools. We believe that the decision to use our curriculum exclusively speaks to the comprehensive nature of the Cloud Nine ESL Program, and provides the kind of positive messaging that our sales team can leverage to the Company’s benefit.”

About Cloud Nine Education Group Ltd.

The Company specializes in the development and sale of its English language curriculum called the Cloud Nine ESL Program. The system is technologically advanced and replaces textbooks with tablets and smart phones which better meets the needs of today highly mobile student base. YouTube videos and internet links are embedded in the curriculum’s core content to create a dynamic and interactive platform. Unlike a textbook based program, the cloud hosted format allows Cloud Nine’s team of curriculum developers to keep pace with world events and provide learning materials that are relevant and engaging for students. The Company also owns and operates an accredited ESL school in Vancouver called Cloud Nine College Ltd.

For more information regarding Cloud Nine, please contact:

Michael Hunter
President and Chief Executive Officer
Telephone: +1.604.377.5572
mhunter@c9eg.com

Forward-Looking Information

Statements in this press release include certain “forward-looking information”. Statements in this news release regarding the Offering and the Company’s use of the proceeds of the Offering contain forward-looking information. Readers are cautioned that actual events may vary from the forward-looking information contained in this news release. Material risk factors that could cause actual results to differ materially from the forward-looking information in this news release include, but are not limited to, changes in market conditions or regulatory requirements applicable to the Offering. The forward-looking information in this news release is based on the assumptions that market conditions and regulatory requirements will not change in any material respect and that the Company will be able to obtain all approvals required for the completion of the Offering, including approval of the Company’s listing on the Canadian Securities Exchange. The Company does not assume any responsibility for updating forward-looking information, except as required by law.

SOURCE: Cloud Nine Education Group Ltd.

ReleaseID: 458020

Upcoming AWS Coverage on KBR, Inc. Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 23, 2017 / Active Wall St. blog coverage looks at the headline from Jacobs Engineering Group Inc. (NYSE: JEC) as the Company announced on March 22, 2017, that it has been appointed by Fucheng Investment Australia (FIA) to lead the conceptualization, planning, and design of a regional center of agribusiness innovation in Australia. The Company also won a Construction management contract from Oxea Corporation a day earlier. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Jacobs Engineering Group’s competitors within the Technical Services space, KBR, Inc. (NYSE: KBR), reported on February 24, 2017, its Q4 FY16 financial results. AWS will be initiating a research report on KBR, Inc. in the coming days.

Today, AWS is promoting its blog coverage on JEC; touching on KBR. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

Jacobs is one of the world’s largest and most diverse providers of full-spectrum technical, professional, and construction services for industrial, commercial, and government organizations globally. The Company employs over 54,000 people and operates in more than 25 countries around the world.

Project Details

Jacobs will be providing a multidisciplinary approach for the proposed development, combining urban planning, design, engineering, economics, and environmental sustainability services.

The appointment follows FIA’s AUS$100 million acquisition of a 4,953-hectare section of Woodhouse Station, a former cattle station on Melbourne’s western urban fringe. Initial concept planning for the site will take place over the coming months.

“We were looking to appoint a global leader in city planning and infrastructure development to help us create something completely unique with Woodhouse Station,” said Fucheng Investment Australia CEO Chris Potaris,” Jacobs stood out as the team who not only understood our vision, but had the ability and experience to deliver it.”

“It is our goal to help FIA deliver a project that is viable at each stage of its development, from a core of intensive agriculture to one that can potentially become a National Employment Cluster for Melbourne,” said Senior Vice President Buildings and Infrastructure Patrick Hill.

Wins Construction Contract

On March 21, 2017, Jacobs announced that it has been awarded a construction management contract from Oxea Corporation for a Propanol Expansion project at its manufacturing site at Bay City, Texas at an undisclosed amount. Propanol is used to manufacture products such as cosmetics and pharmaceuticals, printing inks, coatings, and adhesives.

Jacobs stated that it will be providing pre-construction planning and construction management services to help deliver the new Propanol 2 unit that will add a capacity of 100,000 metric ton per year of propanol and 40,000 metric ton per year of propionaldehyde. The facility is scheduled to commence operations in 2018. Once commissioned, the unit will enable Oxea for future growth and increased market demand. Oxea is already the largest producer of propanol worldwide, and one of the world’s leading suppliers of Oxo products such as alcohols, aldehydes, and acids.

“This project reflects our long-term selective growth strategy,” said Oxea Executive Vice President Global Sales and Oxo-Intermediates Purnendu Rai, “It helps us reinforce our strong position as the largest producer of propanol worldwide. Propanol 2 will provide Oxea with opportunities for further expansion into profitable growth areas.”

Stock Performance

Jacobs Engineering’s share price finished yesterday’s trading session at $54.78, marginally up 0.46%. A total volume of 603.57 thousand shares exchanged hands. The stock has advanced 10.04% and 23.17% in the last six months and past twelve months, respectively. The stock is trading at a PE ratio of 29.61 and has a dividend yield of 1.10%. At Wednesday’s closing price, the stock’s net capitalization stands at $6.63 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458001

Upcoming AWS Coverage on US Silica Holdings Post-Earnings Results

LONDON, UK / ACCESSWIRE / March 23, 2017 / Active Wall St. announces its post-earnings coverage on Tahoe Resources Inc. (NYSE: TAHO). The Company posted its fourth quarter fiscal 2016 (Q4 FY16) and full year fiscal 2016 (FY16) earnings on March 09, 2017. The Vancouver, British Columbia-based Company’s achieved production and cost guidance for the third consecutive year. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of Tahoe Resources’ competitors within the Industrial Metals & Minerals space, US Silica Holdings, Inc. (NYSE: SLCA), reported on February 22, 2017, its Q4 and full year 2016 results. AWS will be initiating a research report on US Silica in the coming days.

Today, AWS is promoting its earnings coverage on TAHO; touching on SLCA. Get our free coverage by signing up to:

http://www.activewallst.com/register/

Earnings Reviewed

During Q4 FY16, Tahoe’s revenues grew to $189.40 million from $154.89 million in Q4 FY15. However, revenues’ number for Q4 FY16 missed market expectations of $229.5 million.

The gold and copper mining Company reported earnings attributable to common shareholders of $0.32 million, or $0.00 per diluted share, in Q4 FY16 versus loss attributable to common shareholders of $107.72 million, or $0.47 loss per diluted share, in the prior year’s comparable quarter. The Company’s adjusted earnings for Q4 FY16 came in at $18.42 million, or $0.06 per share, compared to $51.01 million, or $0.22 per share, in Q4 FY15. Additionally, Wall Street had expected the Company to report adjusted earnings of $0.16 per diluted share.

Tahoe’s revenues rose during FY16 to $784.50 million from $519.72 million in FY15. The Company’s earnings attributable to common shareholders for FY16 were $117.88 million, or $0.41 per diluted share, compared to a loss attributable to common shareholders of $71.91 million, or $0.35 loss per diluted share, in FY15. Furthermore, adjusted earnings for FY16 stood at $180.39 million, or $0.62 per diluted share, versus $98.91 million, or $0.48 per diluted share, in FY15.

Production Numbers

Silver – In Q4 FY16, silver production volume was 4.83 million ounces, up from 5.22 million ounces, in last year’s comparable quarter. For the reported quarter, cash costs net of by-product credits attribute to silver production increased to $6.48 per ounce from $2.23 per ounce in Q4 FY15. The all-in sustaining costs associated with silver production increased to $9.76 per ounce in Q4 FY16 from $4.85 per ounce in Q4 FY15.

Tahoe reported silver production volume of 21.27 million ounce in FY16, beating FY16 silver production guidance range of 18 million ounce to 21 million ounce. The total silver cash cost in FY16 was $5.84 per ounce compared to guidance of $5.50 per ounce and $6.50 per ounce. Furthermore, all-in sustaining costs for silver during FY16 were $8.06 per ounce, which was in-line with the Company’s guidance range of $8.00 per ounce to $9.00 per ounce.

Gold- The Company’s gold production volume in Q4 FY16 was 119.9 thousand ounces, compared to 59.8 thousand ounces in the previous year’s same quarter. The gold cash costs net of by-product credits increased during Q4 FY16 to $594 per ounce from $541 per ounce in Q4 FY15. The gold’s all-in sustaining costs were $945 per ounce in Q4 FY16 versus $774 per ounce in the prior year’s comparable period.

The gold production volume for full-year FY16 was 385.1 thousand ounces, meeting the Company’s gold production guidance range of 370 thousand ounces to 430 thousand ounces. Total cash cost associated with gold production during FY16 was $620 per ounce compared to guidance range of $675 per ounce to $725 per ounce. Additionally, gold all-in sustaining costs for FY16 came in at $943 per ounce versus the Company’s guidance range of $950 per ounce to $1,000 per ounce.

Cash Flow and Balance Sheet

In the three months ended December 31, 2016, net cash generated by operating activities rose to $107.02 million from $54.16 million in Q4 FY15. As on December 31, 2016, cash and cash equivalents balances stood at $163.37 million compared to $108.67 million as on December 31, 2015. Furthermore, the Company’s total non-current liabilities position stood at $348.66 million as on December 31, 2016, compared to $187.55 million as on December 31, 2015.

Dividend

In a separate press release on March 09, 2017, Tahoe’s Board of Directors declared the third monthly dividend for 2017 of $0.02 per common share. The monthly dividend is payable on Thursday, March 30, 2017, to shareholders of record at the close of business on Thursday, March 23, 2017.

Earnings Outlook

The Company in its outlook for full year FY17 anticipates silver production in the range of 18 million to 21 million ounces. The Company projects cash cost applicable to silver during FY17 to be between $7.00 and $8.00 per ounce. Additionally, silvers’ all-in sustaining costs guidance range for FY17 is $9.50 to $10.50 per ounce to $1,250 per ounce.

For gold, the production guidance range for FY17 is of 375 thousand to 4.25 thousand ounces. The Company forecasts cash cost applicable to gold during FY17 to be between $700 and $750 per ounce. Furthermore, all-in sustaining costs guidance range for gold is anticipated to be in the range of $1,150 per ounce to $1,250 per ounce.

Stock Performance

At the close of trading session on Wednesday, March 22, 2017, Tahoe Resources’ stock price slipped 1.06% to end the day at $7.46. A total volume of 2.05 million shares were exchanged during the session. Furthermore, the stock is trading at a PE ratio of 207.22 and has a market cap of $2.32 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 458005

LOS ANGELES, CA / ACCESSWIRE / March 23, 2017 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that it has entered into a sponsored research agreement with the University of Minnesota to conduct a toxicity study of its TriKE cancer treatment (OXS-3550), a required step before researchers can apply for a Phase 1 clinical trial with the Food and Drug Administration.

Under the agreement, Oxis will pay for the university to conduct a study that will determine the optimal dose for OXS-3550. The research will be led by Dr. Daniel Vallera, Director of the section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center. He is a member of the Scientific Advisory Board of Oxis’ wholly owned subsidiary, Oxis Biotech Inc.

Oxis and the University of Minnesota have reached a licensing agreement under which Oxis holds the worldwide rights to commercialize the TriKE therapy, once it receives regulatory approval.

“The agreement will support the TriKE toxicology studies that are needed for an FDA submission, which we expect to file soon,” said Dr. Jeffrey Miller, Deputy Director of the University of Minnesota Masonic Cancer Center. “We are excited to see this drug development move forward.”

Dr. Vallera and Dr. Miller were instrumental in developing Trispecific Killer Engager (TriKE) cancer therapy and Bispecific Killer Engager (BiKE). Both platforms have been licensed by Oxis. The BiKE therapy, OXS-1550, is currently in an FDA Phase 1/Phase 2 clinical trial in Minnesota.

Both treatments empower the body’s immune system to identify and selectively kill cancer cells, while leaving healthy cells alone.

Dr. Vallera has spent 35 years with the University of Minnesota’s cancer center, where he oversees a laboratory specializing in the development of biological recombinant drugs focusing on bispecific antibody therapies that directly deliver toxic signals to cancer cells.

About Oxis Biotech, Inc.: Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS’ lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug’s cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS’ lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Forward-Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company website: www.oxis.com.

Media contact:

Stuart Pfeifer, Sitrick & Co.
(310) 788-2850, or spfeifer@sitrick.com

SOURCE: Oxis International Inc.

ReleaseID: 457985

PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / March 23, 2017 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, today announces that the Company will file its financial results for the three and 12 months ended December 31, 2016 with the U.S. Securities and Exchange Commission (“SEC”) before the opening of the U.S. financial markets on March 30, 2017. The Form 20F will include audited consolidated financial statements, as well as additional information regarding the Company. The Form 20F will be available at www.sec.gov and at www.rosettagenomics.com.

Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of Rosetta Genomics, will host a conference call on Thursday, March 30, 2017 at 10:00 a.m. Eastern time to provide an update on the Company’s business and respond to questions.

Individuals interested in listening to the conference call may do so by dialing (866) 239-5859, or for international callers (702) 495-1913. The conference ID number is 92837292. The call will be available through webcast, which can be accessed on the investor relations section of the Company’s website at www.rosettagx.com.

A telephone replay will be available through April 5, 2017 by dialing (855) 859-2056 or for international callers (404) 537-3406, and entering the Conference ID number 92837292. The webcast will be available on the Company’s website for 30 days following the completion of the call.

About Rosetta Genomics

Rosetta is pioneering the field of molecular diagnostics by offering rapid and accurate diagnostic information that enables physicians to make more timely and informed treatment decisions to improve patient care. Rosetta has developed a portfolio of unique diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists and other specialists to help them deliver better care to their patients. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of cancer in thyroid nodules, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company’s Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the “Risk Factors” section of Rosetta’s most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Rosetta Genomics Contact:
Ken Berlin, President & CEO
(267) 298-1159
investors@rosettagx.com

Rosetta Genomics Investor Contact:
LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com

SOURCE: Rosetta Genomics Ltd.

ReleaseID: 457966

Helomics-SCOPE USA Partnership Provides Pharmaceutical and Diagnostic Companies with a Single Partner Capable of Providing a Complete Range of Pre-Clinical and Clinical Trial Services

PITTSBURGH, PA / ACCESSWIRE / March 23, 2017 / Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SCOPE International USA, Inc. (SCOPE USA), the North American office of an independent, full-service, contract research organization offering a complete range of clinical development services to the pharmaceutical, biotechnology, and medical device industries, today announced the completion of a strategic agreement to co-market products and services. Under the terms of the agreement, Helomics and SCOPE USA will collaborate to identify, develop, and facilitate new business opportunities with potential partners in the pharmaceutical, biotechnology, clinical diagnostics, medical device, and clinical research industries.

Alethea Wieland, President and Managing Director of North American Operations for SCOPE USA said, “We are very pleased to be partnering with Helomics, a recognized leader in oncology for personalized medicine diagnostic assay development and commercialization. This critical partnership with Helomics will augment and complement our U. S. and international business services in the ever-increasing complex fields of oncology and personalized medicine.”

“We are looking forward to collaborating with SCOPE USA in identifying new business initiatives that will benefit both organizations,” stated Gerald J. Vardzel Jr., President and CEO of Helomics. “SCOPE’s global presence combined with our strong clinical diagnostics presence in North America will yield synergistic commercial opportunities for us and value for our clients.”

Donald L. Very, Jr., PhD, Vice President of Research and Commercial Development at Helomics commented, “SCOPE International is a leading provider of comprehensive clinical trial design and management services. Their expertise, products, and services are a unique complement to ours and together, we can provide a comprehensive set of preclinical and clinical trial services to our partner-clients in the pharmaceutical, diagnostic, and medical device industries.”

About Helomics® Corporation

Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. Helomics offers advanced clinical laboratory diagnostic tests as well as scientific and non-scientific product enhancement services to provide a customized solution to our client’s specific product development needs.

Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories. For more information please visit: www.helomics.com.

About SCOPE International USA, Inc.

SCOPE International USA, Inc., located in Pittsburgh, Pennsylvania, is the North American office of a privately held, independent, full-service contract research organization offering a complete range of clinical development and consulting services to the pharmaceutical, biotechnology, and medical device industries. With 17 offices in Western and Eastern Europe, United Kingdom, Ukraine, Russia, and the United States, SCOPE’s dedicated staff cover more than 30 countries. For more information please visit: www.scope-international.com.

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For more information regarding Helomics Corporation, please contact:

Michelle Murgia, Marketing Communications and Design
Helomics Corporation
mmurgia@helomics.com
412-432-1363

For more information regarding SCOPE International USA, Inc., please contact:

Alethea Wieland, President and Managing Director (North American Operations)
SCOPE International USA, Inc.
awieland@scope-international.com
724-272-1245

SOURCE: Helomics® Corporation

ReleaseID: 457965

SPRINGFIELD, VA / ACCESSWIRE / March 23, 2017 / Versar, Inc. (NYSE MKT: VSR) today announced that the United States Army Corps of Engineers, Transatlantic Afghanistan District (USACE-TAA), has awarded a new contract to Versar for up to four years valued at over $2.3 million. Versar will provide Operations, Maintenance, and Support Services at USACE-TAA facilities throughout Afghanistan.

Tony Otten, Chief Executive Officer of Versar, said, “Our skilled workforce of Service Managers, Electricians, Plumbers, and Custodians are deployed across Afghanistan and began supporting this contract on March 1, 2017. This is a solid addition to Versar’s portfolio of engineering and project management services currently provided in Afghanistan.”

VERSAR, INC., headquartered in Springfield, Virginia, is a publicly-traded global project management company providing sustainable value oriented solutions to government and commercial clients in the construction management, environmental services, and professional services market areas.

VERSAR operates the following websites: www.versar.com and www.versarpps.com.

Find out more about VERSAR at:

Twitter: https://twitter.com/VersarInc
Facebook: https://www.facebook.com/VersarInc
LinkedIn: http://www.linkedin.com/company/38251

This news release contains forward-looking information. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be significantly impacted by certain risks and uncertainties described herein and in Versar’s Annual Report on Form 10-K filed with the Securities and Exchange Commission for the fiscal year ended June 26, 2015, as updated from time to time in the Company’s periodic filings. The forward-looking statements are made as of the date hereof and Versar does not undertake to update its forward-looking statements.

Contact:

Karin Weber
M&A, Investor Relations Manager
Versar, Inc.
(703) 642-6706
kweber@versar.com

Robert Ferri
Robert Ferri Partners
(415) 575-1589
robert.ferri@robertferri.com

SOURCE: Versar, Inc.

ReleaseID: 457955